Transcranial magnetic stimulation and ketamine: implications for combined treatment in depression
暂无分享,去创建一个
[1] Marcel Green,et al. Interventional Mental Health: A Transdisciplinary Approach to Novel Psychiatric Care Delivery , 2023, Cureus.
[2] P. Lespérance,et al. Intravenous ketamine for treatment-resistant depression patients who have failed to respond to transcranial magnetic stimulation: A case series. , 2023, Journal of affective disorders.
[3] R. Schoevers,et al. Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability. , 2022, The lancet. Psychiatry.
[4] P. Lespérance,et al. Transcranial magnetic stimulation and intravenous ketamine combination therapy for treatment-resistant bipolar depression: A case report , 2022, Frontiers in Psychiatry.
[5] Zhenyu Hu,et al. The molecular pathophysiology of depression and the new therapeutics , 2022, MedComm.
[6] R. Cui,et al. Uncovering the Underlying Mechanisms of Ketamine as a Novel Antidepressant , 2022, Frontiers in Pharmacology.
[7] Renhong He,et al. Repetitive transcranial magnetic stimulation promotes neurological functional recovery in rats with traumatic brain injury by upregulating synaptic plasticity-related proteins , 2022, Neural regeneration research.
[8] SJ McPherson,et al. Psychological treatments for persistent depression: A systematic review and meta-analysis of quality of life and functioning outcomes. , 2022, Psychotherapy.
[9] Supplemental Material for Psychological Treatments for Persistent Depression: A Systematic Review and Meta-Analysis of Quality of Life and Functioning Outcomes , 2022, Psychotherapy.
[10] J. González-Olvera,et al. 5 Hz of repetitive transcranial magnetic stimulation improves cognition and induces modifications in hippocampal neurogenesis in adult female Swiss Webster mice , 2022, Brain Research Bulletin.
[11] Nelson B Rodrigues,et al. Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis. , 2022, Journal of psychiatric research.
[12] Jianguo Chen,et al. Repetitive transcranial magnetic stimulation exerts anti-inflammatory effects via modulating glial activation in mice with chronic unpredictable mild stress-induced depression. , 2022, International immunopharmacology.
[13] G. Kranz,et al. The Impact of Theta-Burst Stimulation on Cortical GABA and Glutamate in Treatment-Resistant Depression: A Surface-Based MRSI Analysis Approach , 2022, Frontiers in Molecular Neuroscience.
[14] J. Port,et al. Neurostructural Differences in Adolescents With Treatment-Resistant Depression and Treatment Effects of Transcranial Magnetic Stimulation , 2022, The international journal of neuropsychopharmacology.
[15] D. Pavel,et al. Brain SPECT as an Imaging Biomarker for Evaluating Effects of Novel Treatments in Psychiatry–A Case Series , 2022, Frontiers in Psychiatry.
[16] A. Sack,et al. A Retrospective Naturalistic Study Comparing the Efficacy of Ketamine and Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression , 2022, Frontiers in Psychiatry.
[17] M. Shigeta,et al. Transcranial magnetic stimulation modalities for psychiatric disorders: Publication trends from 1985 to 2019 , 2021, Neuropsychopharmacology reports.
[18] F. Ye,et al. Author Correction: Structural basis of ketamine action on human NMDA receptors , 2021, Nature.
[19] K. Kuypers,et al. Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics , 2021, Frontiers in Psychiatry.
[20] F. Ye,et al. Structural basis of ketamine action on human NMDA receptors , 2021, Nature.
[21] Á. Pascual-Leone,et al. Day-to-day variability in motor threshold during rTMS treatment for depression: Clinical implications , 2021, Brain Stimulation.
[22] A. Young,et al. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation. , 2021, The American journal of psychiatry.
[23] Oscar G. Morales,et al. Borderline personality traits do not influence response to TMS. , 2020, Journal of affective disorders.
[24] S. Rossi,et al. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines , 2020, Clinical Neurophysiology.
[25] M. Cacic,et al. Therapeutic Mechanisms of Ketamine. , 2020, Psychiatria Danubina.
[26] C. Zarate,et al. Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. , 2020, Journal of affective disorders.
[27] W. Marcantoni,et al. A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009 - January 2019. , 2020, Journal of affective disorders.
[28] S. Dursun,et al. Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers , 2020, Therapeutic Advances in Psychopharmacology.
[29] Sa-Ik Hong,et al. Rodent models for psychiatric disorders: problems and promises , 2020, Laboratory Animal Research.
[30] K. Sudheimer,et al. Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression. , 2020, The American journal of psychiatry.
[31] S. Rossi,et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018) , 2019, Clinical Neurophysiology.
[32] R. Duman,et al. Neuroplasticity in cognitive and psychological mechanisms of depression: An integrative model , 2019, Molecular Psychiatry.
[33] K. Hashimoto,et al. Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites , 2019, Translational Psychiatry.
[34] D. Pavel,et al. Combination therapy with transcranial magnetic stimulation and ketamine for treatment-resistant depression: A long-term retrospective review of clinical use , 2019, Heliyon.
[35] R. Cho,et al. Neurophysiological Effect of Ketamine on Prefrontal Cortex in Treatment-Resistant Depression: A Combined Transcranial Magnetic Stimulation–Electroencephalography Study , 2019, Chronic stress.
[36] T. Blackburn. Depressive disorders: Treatment failures and poor prognosis over the last 50 years , 2019, Pharmacology research & perspectives.
[37] Jennifer W. Evans,et al. Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration , 2018, Biological Psychiatry.
[38] D. S. del Ángel,et al. Neuroprogression: the hidden mechanism of depression , 2018, Neuropsychiatric disease and treatment.
[39] Teddy J. Akiki,et al. Ketamine, but Not the NMDAR Antagonist Lanicemine, Increases Prefrontal Global Connectivity in Depressed Patients , 2018, Chronic stress.
[40] S. Dursun,et al. Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness , 2018, Journal of psychopharmacology.
[41] J. Ramos-Quiroga,et al. Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review , 2018, CNS Drugs.
[42] Jonathan Downar,et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial , 2018, The Lancet.
[43] T. Gould,et al. Mechanisms of ketamine action as an antidepressant , 2018, Molecular Psychiatry.
[44] S. Thompson,et al. Convergent Mechanisms Underlying Rapid Antidepressant Action , 2018, CNS Drugs.
[45] M. Milak,et al. Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial. , 2017, The American journal of psychiatry.
[46] E. Ballard,et al. The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. , 2017, The American journal of psychiatry.
[47] A. Phillips,et al. Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism , 2017, Journal of psychiatry & neuroscience : JPN.
[48] J. Sato,et al. The Nucleus Accumbens and Ketamine Treatment in Major Depressive Disorder , 2017, Neuropsychopharmacology.
[49] Elisabeth Bernhardt,et al. Using neuroimaging to individualize TMS treatment for depression: Toward a new paradigm for imaging-guided intervention , 2017, NeuroImage.
[50] G. Thickbroom,et al. Repetitive Transcranial Magnetic Stimulation of the Brain , 2017, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.
[51] T. Han,et al. Repetitive Transcranial Magnetic Stimulation to the Unilateral Hemisphere of Rat Brain. , 2016, Journal of visualized experiments : JoVE.
[52] E. Seifritz,et al. Differential effects of rumination and distraction on ketamine induced modulation of resting state functional connectivity and reactivity of regions within the default-mode network. , 2016, Social cognitive and affective neuroscience.
[53] K. Hagi,et al. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories , 2016, Psychological Medicine.
[54] M. Frye,et al. Transcranial magnetic stimulation potentiates glutamatergic neurotransmission in depressed adolescents , 2016, Psychiatry Research: Neuroimaging.
[55] T. Svensson,et al. Ketamine-like effects of a combination of olanzapine and fluoxetine on AMPA and NMDA receptor-mediated transmission in the medial prefrontal cortex of the rat , 2015, European Neuropsychopharmacology.
[56] C. Duarte,et al. Regulation of hippocampal synaptic plasticity by BDNF , 2015, Brain Research.
[57] M. Piradov,et al. Possible Mechanisms Underlying the Therapeutic Effects of Transcranial Magnetic Stimulation , 2015, Front. Hum. Neurosci..
[58] S. Best. Combined ketamine and transcranial magnetic stimulation for treatment resistant depression in the context of chronic OCD: a case report , 2015 .
[59] K. Laws,et al. The use of ketamine as an antidepressant: a systematic review and meta‐analysis , 2015, Human psychopharmacology.
[60] D. Pavel,et al. Ketamine and transcranial magnetic stimulation treatment for bipolar II disorder: a case report , 2015, Journal of Medical Case Reports.
[61] P. Blier,et al. Impact of subanesthetic doses of ketamine on AMPA-mediated responses in rats: An in vivo electrophysiological study on monoaminergic and glutamatergic neurons , 2015, Journal of psychopharmacology.
[62] S. Best,et al. Combination therapy utilizing ketamine and transcranial magnetic stimulation for treatment-resistant depression: a case report , 2015, The International journal of neuroscience.
[63] S. Best. Combined ketamine/transcranial magnetic stimulation treatment of severe depression in bipolar I disorder. , 2014, The journal of ECT.
[64] Zhi-qiang Zhou,et al. Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex , 2014, European Psychiatry.
[65] R. Steven,et al. Rapid Relief of Treatment Resistant Depression by Facilitated Ketamine Infusion: A Preliminary Report , 2014 .
[66] M. Merzenich,et al. Brain plasticity-based therapeutics , 2014, Front. Hum. Neurosci..
[67] C. Pittenger. Disorders of memory and plasticity in psychiatric disease , 2013, Dialogues in clinical neuroscience.
[68] D. Charney,et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. , 2013, The American journal of psychiatry.
[69] Zhi-qiang Zhou,et al. Acute administration of ketamine in rats increases hippocampal BDNF and mTOR levels during forced swimming test , 2013, Upsala journal of medical sciences.
[70] P. Schwenkreis,et al. Influence of (S)-ketamine on human motor cortex excitability , 2012, Experimental Brain Research.
[71] S. Kito,et al. Cerebral blood flow ratio of the dorsolateral prefrontal cortex to the ventromedial prefrontal cortex as a potential predictor of treatment response to transcranial magnetic stimulation in depression , 2012, Brain Stimulation.
[72] H. Solvason,et al. TRANSCRANIAL MAGNETIC STIMULATION (TMS) FOR MAJOR DEPRESSION: A MULTISITE, NATURALISTIC, OBSERVATIONAL STUDY OF ACUTE TREATMENT OUTCOMES IN CLINICAL PRACTICE , 2012, Depression and anxiety.
[73] David L. Hunt,et al. Synaptic plasticity of NMDA receptors: mechanisms and functional implications , 2012, Current Opinion in Neurobiology.
[74] C. Belzung,et al. Criteria of validity for animal models of psychiatric disorders: focus on anxiety disorders and depression , 2011, Biology of Mood & Anxiety Disorders.
[75] Abraham Zangen,et al. Long-Term Effects of Repetitive Transcranial Magnetic Stimulation on Markers for Neuroplasticity: Differential Outcomes in Anesthetized and Awake Animals , 2011, The Journal of Neuroscience.
[76] Á. Pascual-Leone,et al. The NeuroStar TMS device: conducting the FDA approved protocol for treatment of depression. , 2010, Journal of visualized experiments : JoVE.
[77] Sarah H. Lisanby,et al. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study , 2010, Brain Stimulation.
[78] D. Charney,et al. Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression , 2010, Biological Psychiatry.
[79] S. Rossi,et al. Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research , 2009, Clinical Neurophysiology.
[80] Yogesh K. Dwivedi. Brain-derived neurotrophic factor: role in depression and suicide , 2009, Neuropsychiatric disease and treatment.
[81] H. Möller,et al. Acute prefrontal rTMS increases striatal dopamine to a similar degree as d-amphetamine , 2007, Psychiatry Research: Neuroimaging.
[82] William W. McDonald,et al. Efficacy and Safety of Transcranial Magnetic Stimulation in the Acute Treatment of Major Depression: A Multisite Randomized Controlled Trial , 2007, Biological Psychiatry.
[83] P. Schlattmann,et al. Metabolic alterations in the dorsolateral prefrontal cortex after treatment with high-frequency repetitive transcranial magnetic stimulation in patients with unipolar major depression. , 2007, Journal of psychiatric research.
[84] Sarah H Lisanby,et al. Antidepressant-Induced Neurogenesis in the Hippocampus of Adult Nonhuman Primates , 2007, The Journal of Neuroscience.
[85] J. Rothwell,et al. The after-effect of human theta burst stimulation is NMDA receptor dependent , 2007, Clinical Neurophysiology.
[86] P. Fitzgerald,et al. A comprehensive review of the effects of rTMS on motor cortical excitability and inhibition , 2006, Clinical Neurophysiology.
[87] E. Schuman,et al. Dendritic Protein Synthesis, Synaptic Plasticity, and Memory , 2006, Cell.
[88] T. Bliss,et al. Plasticity in the human central nervous system. , 2006, Brain : a journal of neurology.
[89] R. Yoshimura,et al. High-frequency repetitive transcranial magnetic stimulation improves refractory depression by influencing catecholamine and brain-derived neurotrophic factors. , 2006, Pharmacopsychiatry.
[90] P. Pasqualetti,et al. Ketamine Increases Human Motor Cortex Excitability to Transcranial Magnetic Stimulation , 2003, The Journal of physiology.
[91] W. Drevets. Neuroimaging studies of mood disorders , 2000, Biological Psychiatry.
[92] John H Krystal,et al. Antidepressant effects of ketamine in depressed patients , 2000, Biological Psychiatry.
[93] A P Rudell,et al. Transcranial magnetic stimulation in study of the visual pathway. , 1998, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.
[94] T. Zyss,et al. Preliminary comparison of behavioral and biochemical effects of chronic transcranial magnetic stimulation and electroconvulsive shock in the rat , 1997, Biological Psychiatry.
[95] Bita Moghaddam,et al. Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex , 1997, The Journal of Neuroscience.
[96] R. Belmaker,et al. The effect of transcranial magnetic stimulation of rat brain on behavioral models of depression , 1995, Brain Research.
[97] Mark Hallett,et al. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression , 1995, Neuroreport.
[98] M. Bear,et al. Synaptic plasticity: LTP and LTD , 1994, Current Opinion in Neurobiology.
[99] M. Merzenich,et al. Cortical plasticity and memory , 1993, Current Opinion in Neurobiology.
[100] Karl J. Friston,et al. The anatomy of melancholia – focal abnormalities of cerebral blood flow in major depression , 1992, Psychological Medicine.
[101] J. Mazziotta,et al. Reduction of prefrontal cortex glucose metabolism common to three types of depression. , 1989, Archives of general psychiatry.
[102] A. Barker,et al. NON-INVASIVE MAGNETIC STIMULATION OF HUMAN MOTOR CORTEX , 1985, The Lancet.
[103] A. Coppen. The Biochemistry of Affective Disorders , 1967, British Journal of Psychiatry.
[104] W. H. Ganti. Conditioned Reflexes and Neuron Organization , 1950 .
[105] A. Nierenberg,et al. Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions , 2023, World psychiatry : official journal of the World Psychiatric Association.
[106] Jennifer W. Evans,et al. Functional MRI markers for treatment-resistant depression: Insights and challenges. , 2023, Progress in brain research.
[107] steveBesta,et al. Combined transcranial Magnetic stimulation and Ketamine for treatment of suicidal ideation , Refractory Mood Disorder , neurotoxicity and pain : a Case Report , 2017 .
[108] B. Bradley,et al. ACNP 56th Annual Meeting: Poster Session I, December 4, 2017 , 2017, Neuropsychopharmacology.
[109] D. Pavel,et al. Combined transcranial magnetic stimulation and ketamine for treatment of refractory mood disorder , anxiety , and pain : A case report , 2017 .
[110] J. C. Rothwell,et al. Magnetic stimulation : motor evoked potentials , 2010 .
[111] 行正 徹. High-frequency repetitive transcranial magnetic stimulation improves refractory depression by influencing catecholamine and brain-derived neurotrophic factors , 2007 .
[112] P. Rossini,et al. Magnetic stimulation: motor evoked potentials. The International Federation of Clinical Neurophysiology. , 1999, Electroencephalography and clinical neurophysiology. Supplement.